|Videos|September 1, 2020
Updates on I/O Therapy for Non-Driver mNSCLC
Advertisement
A review of new FDA approvals in I/O therapy regarding a nivolumab/ipilimumab-based regimen as seen in the CheckMate 227 and CheckMate 9LA studies, along with considerations for immune-related adverse events.
Data from the following clinical trials are discussed:
CheckMate 227: Nivolumab plus ipilimumab in advanced non–small cell lung cancer (Hellmann MD et al. N Engl J Med. 2019;381:2020-2031.)
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: Three-year update from CheckMate 227 Part 1. (Ramalingam SS et al. 2020 ASCO annual meeting. Abstract 9500.)
Nivolumab + ipilimumab + 2 cycles of platinum-doublet chemotherapy vs 4 cycles chemo as first-line treatment for stage IV/recurrent non–small cell lung cancer: CheckMate 9LA. (Reck M et al. 2020 ASCO annual meeting. Abstract 9501.)
IMpower110: Clinical safety in a phase III study of atezolizumab monotherapy vs platinum-based chemotherapy in first-line non–small cell lung cancer. (Jassem J et al. 2020 ASCO annual meeting. Abstract e21623.)
Advertisement
Related to this article
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.
OS was not improved with sigvotatug vedotin vs docetaxel in patients with pretreated, locally advanced, unresectable, or metastatic nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
5